Cargando…

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options

SIMPLE SUMMARY: Incidence of biliary tract cancer is increasing, and patients are frequently diagnosed with unresectable or metastatic disease, when therapeutic options are limited. Due to these reasons, prognosis remains poor and new systemic treatment options are urgently needed. This article revi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Personeni, Nicola, Lleo, Ana, Pressiani, Tiziana, Colapietro, Francesca, Openshaw, Mark Robert, Stavraka, Chara, Pouptsis, Athanasios, Pinato, David James, Rimassa, Lorenza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696875/ https://www.ncbi.nlm.nih.gov/pubmed/33202975 http://dx.doi.org/10.3390/cancers12113370

Ejemplares similares

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2020)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
por: Personeni, Nicola, et al.
Publicado: (2018)

Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019)

Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights
por: Cammarota, Antonella, et al.
Publicado: (2022)

Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations
por: Pouptsis, Athanasios, et al.
Publicado: (2020)

Current options and future directions of systemic therapy for advanced biliary tract cancer
por: Prete, Maria Giuseppina, et al.
Publicado: (2021)

The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges
por: D’Alessio, Antonio, et al.
Publicado: (2021)

PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
por: Colapietro, Francesca, et al.
Publicado: (2023)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
por: Zanuso, Valentina, et al.
Publicado: (2023)

Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment
por: Personeni, Nicola, et al.
Publicado: (2022)

Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner
por: Campani, Claudia, et al.
Publicado: (2020)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Personeni, Nicola, et al.
Publicado: (2021)

Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients
por: Milana, Flavio, et al.
Publicado: (2022)

Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients
por: Stavraka, Chara, et al.
Publicado: (2019)

Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2021)

Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
por: Hajiev, Saur, et al.
Publicado: (2020)

KRAS mutation in lung metastases from colorectal cancer: prognostic implications
por: Ghidini, Michele, et al.
Publicado: (2015)

Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study
por: Personeni, Nicola, et al.
Publicado: (2022)

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option
por: Simone, Valeria, et al.
Publicado: (2017)

Myosteatosis Is Not Associated with Complications or Survival in HCC Patients Undergoing Trans Arterial Embolization
por: Masetti, Chiara, et al.
Publicado: (2022)

Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine
por: Malenica, Ines, et al.
Publicado: (2020)

New and emerging treatment options for biliary tract cancer
por: Noel, Marcus S, et al.
Publicado: (2013)

Systemic treatment options for advanced biliary tract carcinoma
por: Xie, Changqing, et al.
Publicado: (2020)

Characterisation of the immune-related transcriptome in resected biliary tract cancers
por: Ghidini, Michele, et al.
Publicado: (2017)

Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions
por: Stavraka, Chara, et al.
Publicado: (2018)

Biliary tract cancer stem cells - translational options and challenges
por: Mayr, Christian, et al.
Publicado: (2017)

Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives
por: Personeni, Nicola, et al.
Publicado: (2021)

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
por: Cammarota, Antonella, et al.
Publicado: (2023)

Antimitochondrial Antibodies: from Bench to Bedside
por: Colapietro, Francesca, et al.
Publicado: (2021)

Clinical, Ethical and Financial Implications of Incidental Imaging Findings: Experience from a Phase I Trial in Healthy Elderly Volunteers
por: Pinato, David J., et al.
Publicado: (2012)

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
por: Pinato, David J., et al.
Publicado: (2020)

Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
por: Jun, Tomi, et al.
Publicado: (2021)

The La-Related Proteins, a Family with Connections to Cancer
por: Stavraka, Chara, et al.
Publicado: (2015)

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Risk Stratification of Cholangiocarcinoma Patients Presenting with Jaundice: A Retrospective Analysis from a Tertiary Referral Center
por: Lleo, Ana, et al.
Publicado: (2021)

ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma
por: Demirtas, Coskun O., et al.
Publicado: (2021)

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fide4lgnlis2odo522l9g1ab7v